欧盟批准Opzelura®(芦可替尼)乳膏:首款无类固醇外用JAK抑制剂问世,专治成人中度特应性皮炎

美股速递
Jul 29

重大突破!欧盟正式批准Opzelura®(芦可替尼)乳膏上市。这款无类固醇外用JAK抑制剂,成为该地区首款用于成人中度特应性皮炎患者的同类创新药物。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10